Risk and Volatility
NovelStem International has a beta of 0.42, suggesting that its stock price is 58% less volatile than the S&P 500. Comparatively, NovelStem International’s rivals have a beta of 0.74, suggesting that their average stock price is 26% less volatile than the S&P 500.
Insider & Institutional Ownership
29.3% of shares of all “Retail stores, not elsewhere classified” companies are owned by institutional investors. 13.6% of NovelStem International shares are owned by company insiders. Comparatively, 16.9% of shares of all “Retail stores, not elsewhere classified” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Earnings & Valuation
This table compares NovelStem International and its rivals revenue, earnings per share and valuation.
Gross Revenue | Net Income | Price/Earnings Ratio | |
NovelStem International | $10,000.00 | -$4.19 million | -0.65 |
NovelStem International Competitors | $8.79 billion | $125.40 million | 5.92 |
Profitability
This table compares NovelStem International and its rivals’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
NovelStem International | -9,166.67% | N/A | -73.18% |
NovelStem International Competitors | -24.98% | -60.66% | -0.89% |
Summary
NovelStem International rivals beat NovelStem International on 8 of the 9 factors compared.
About NovelStem International
NovelStem International Corp., a development stage biotechnology holding company, focuses on development and commercialization of stem cell-based diagnostic technology for cancer treatments and to reduce resistance to chemotherapy. The company was formerly known as Hollywood Media Corp. and changed its name to NovelStem International Corp. in September 2018. NovelStem International Corp. was incorporated in 1993 and is headquartered in Boca Raton, Florida.
Receive News & Ratings for NovelStem International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovelStem International and related companies with MarketBeat.com's FREE daily email newsletter.